Drug treating breast cancer may be effective in treating lung and ovarian cancer

Drug Treating Breast Cancer May Be Effective In Treating Lung And Ovarian Cancer article is one based on the Health and Medical Updates class, written over our reporter Linda Norton much as February 5, 2019, this paragraph maybe want to search just after that tags list Breast, cancer, drug, effective, lung, ovarian, treating. We are blissful to pleasant you as well providing the another paragraph concerning health along with I always publishing that blogpost daily.

DNA Genetics 620x480.jpg

Two new papers, published simultaneously in Nature Communications and led by researchers at McGill University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare and one common form.

The breakthrough discovery launching this research came in 2014 when Dr. William Foulkes, James McGill Professor in the Departments of Medicine, Oncology and Human Genetics at McGill’s Faculty of Medicine, showed that small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a rare but highly fatal cancer which primarily strikes younger women, is caused by mutations in the gene SMARCA4.

The challenge became how to find a way to exploit this genetic deficiency to better treat these patients. Stepping up to the challenge was Dr. Sidong Huang, Assistant Professor in the Department of Biochemistry at McGill’s Faculty of Medicine, and senior author on both papers. Having trained for many years in Functional Genomics, Dr. Huang joined McGill with the goal of working on important problems in oncology. “Working on something like SCCOHT seemed an obvious choice as it is a unique genetic disease driven by loss of a single gene, SMARCA4,” explains Dr. Huang, who is also a member of McGill’s Goodman Cancer Research Centre.

A collaboration between Dr. Huang and Dr. Foulkes ensued, along with fellow McGill Professor Dr. Janusz Rak at the Research Institute of the McGill University Health Centre (RI-MUHC), Dr. Barbara Vanderhyden at the Ottawa Hospital Research Institute and Dr. Sriram Venneti at the University of Michigan. Through their work, Dr. Huang and his PhD student Yibo Xue, the papers’ first author, were able to identify that targeting the cyclin-dependent kinases 4/6 (CDK4/6) exposed a vulnerability in SMARCA4-deficient cancers.

“What’s clinically exciting about this work is that CDK4/6 inhibitors have been used for years, so they are very well known and their safety profile is established,” notes Dr. Foulkes who is also Head of the Cancer Genetics Laboratory at the Lady Davis Institute of the Jewish General Hospital and a researcher at the RI-MUHC.

“In the case of SCCOHT, in particular, it is encouraging to find existing drugs that may prove effective because this is such a rare cancer that it is unlikely to be the subject of dedicated drug development,” adds Dr. Huang. “Furthermore, patients may also benefit from the anti-tumor immunity triggered by CDK4/6 inhibitors as recently shown in other cancers, in addition to the direct tumor inhibition by these drugs”.

Although much more common than SCCOHT, non-small cell lung cancer (NSCLC) can be very difficult to cure. “We extended the SCCOHT work to NSCLC as we realized about 10% of these common tumors also lack SMARCA4,” explains Xue.

Evidence has been obtained both in vitro on human cancer cells, and in vivo on animal models that CDK inhibitors are effective at quelling SMARCA4-deficient tumors.

“The fact these drugs worked so well was a bit surprising,” says Dr. Foulkes. “Perhaps it works because the protein which is targeted is at critically low levels in the tumor – just enough to keep the tumor alive, but still susceptible to blocking.”

“This is in contrast to the initial application of this class of drugs to treat breast cancers that often express elevated levels of the same protein,” adds Dr. Huang. “Thus, our findings potentially broaden the applications of these drugs.”

The precise mechanism by which these particular inhibitors work in the different cancers is yet to be definitively determined. But, says Dr. Foulkes, this is an academic question; so long as the drugs proves effective, the clinical impact is undeniable.

“The next step is seeing if these drugs work in patients with SCCOHT or NSCLC with SMARCA4 deficiency and identifying other additional drug targets in these cancers to be inhibited in combination with CDK4/6 inhibitors to overcome potential resistance,” says Dr. Huang.

“The dream would be to cure these cancers, but any hint of a response would be a positive step forward, in particular because current treatments for women stricken with SCCOHT have limited effectiveness,” concludes Dr. Foulkes.



You maybe want to gather others paragraph health during our affiliated blogpost or you might want to review on top of noted paragraph, we always updating these health paragraph daily for advise moreover information and trick that one may saving our health as well living these healthy lifestyle. These section is published on Linda Norton with this title Drug Treating Breast Cancer May Be Effective In Treating Lung And Ovarian Cancer.

Related posts of "Drug treating breast cancer may be effective in treating lung and ovarian cancer"

Marine snail venom could improve insulin for diabetic patients — ScienceDaily

Although moderately mobile, marine cone snails have perfected several strategies to capture prey. Some fish-hunting species release venom into the surrounding water. Within the plume of toxic venom, the fish succumbs to fast-acting insulin that renders it immobile. As the fish flounders, the snail emerges from its shell to swallow the pacified victim whole. Researchers...

FSU study breaks new ground in the battle against malignant pediatric brain cancers

Scientists are making important progress in the battle against a class of devilishly complex human pediatric brain cancers thanks to a new study from a team of Florida State University students and faculty. Among young children, there's no brain tumor more common than medulloblastoma. But no specific and effective therapy yet exists for this dangerous...

Study reveals complementary medicine use remains hidden to conventional medicine providers

Credit: CC0 Public Domain Research reveals that 1 in 3 complementary medicine (CM) users do not disclose their CM use to their medical providers, posing significant direct and indirect risks of adverse effects and harm due to unsafe concurrent use of CM and conventional medicine use. The first international systematic review conducted by researchers at...

MUSC researchers examine the way estrogen affects drug addiction

Male rats have held steady as the focus of most addiction studies in the past. But as the field begins to take female rats into account, scientists see that drugs like methamphetamine affect the sexes differently, suggesting the basis for a change in addiction treatment. "The brain changes when you've been addicted to methamphetamine," said...

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.